With MDMA debate spreading beyond biotech, Lykos CEO tries to dispel efficacy, safety concerns

A week after an FDA committee declined to support an midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD), Lykos Therapeutics is looking to dispel some concerns about the therapy as the discussion has taken on a life of its own beyond the biotech world.